Tier 1 — highest

Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women

M H J Knapen, N E Drummen, E Smit, C Vermeer, E Theuwissen
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2013 24(9):2499-507

Bibliography

PubMed
PMID 23525894
DOI
10.1007/s00198-013-2325-6
Funding
Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled clinical trial
ModelHuman participants
Sample244 healthy postmenopausal women
InterventionMK-7 180 μg/day or placebo
Duration3 years
EndpointsBone density and mineral content; Estimated bone strength; Osteocalcin carboxylation

What the study showed, in plain terms

This publication examines bone density and mineral content, estimated bone strength, osteocalcin carboxylation. Study population or evidence base: 244 healthy postmenopausal women. Intervention or exposure: MK-7 180 μg/day or placebo.

Key findings

MK-7 improved vitamin K status and reduced bone loss at the lumbar spine and femoral neck, with no significant total-hip benefit. Some estimated bone-strength measures also favored supplementation.

What this study can and cannot tell us

Results concern postmenopausal women and selected skeletal measures. The arterial-stiffness publication uses this same cohort; the study does not establish broad fracture prevention.

Related papers in the corpus

Tier 1
Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial
Marjo H J Knapen et al. · Thrombosis and haemostasis · 2015
Tier 1
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
S H Rønn et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
Tier 1
Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women
Sofie Hertz Rønn et al. · European journal of endocrinology · 2016
Tier 1
Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial
N Emaus et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010
Tier 1
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
Yingfeng Zhang et al. · Calcified tissue international · 2020
Tier 1
Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women
M H J Knapen et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research